Webster K Cavenee

发表

Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization

W. Cavenee, F. Furnari, Mirko H. H. Schmidt, 2003, Proceedings of the National Academy of Sciences of the United States of America.

mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc.

Feng Liu, Ivan Babic, Paul S Mischel, 2013, Cell metabolism.

Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma.

Paul S Mischel, Timothy F Cloughesy, Kenta Masui, 2016, Cancer cell.

Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of ΔEGFR.

Lixia Diao, Raymond Sawaya, Keith Baggerly, 2011, Journal of proteome research.

De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.

Ivan Babic, Paul S Mischel, Harley I Kornblum, 2013, Cancer discovery.

Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

Ivan Babic, Paul S Mischel, Timothy F Cloughesy, 2011, Cancer discovery.

Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE

Brian M Alexander, Mitchel S Berger, Timothy F Cloughesy, 2017, Clinical Cancer Research.

A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments.

Paul S Mischel, Kenta Masui, P. Mischel, 2013, Carcinogenesis.

Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma

Forest M White, Akitake Mukasa, Ryan A. Flynn, 2007, Proceedings of the National Academy of Sciences.

EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer.

Douglas L Black, Ivan Babic, Paul S Mischel, 2013, Cell metabolism.

Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity.

Ming Li, Stefano Volinia, David H Gutmann, 2014, Cancer research.

Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma.

Hiroyuki Nishimori, James P Basilion, Wadih Arap, 2011, The Journal of clinical investigation.

Methylation Profiling Identifies Epigenetic Markers for High-grade Gliomas.

Tim Hui-Ming Huang, Pearlly S Yan, O. Wiestler, 2004, Cancer genomics & proteomics.

Emerging insights into the molecular and cellular basis of glioblastoma.

Lynda Chin, William C Hahn, Gavin P Dunn, 2012, Genes & development.

Heterogeneity maintenance in glioblastoma: a social network.

W. Cavenee, F. Furnari, M. Inda, 2011, Cancer research.

Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor

W. Cavenee, K. Arden, Webster K Cavenee, 2008, Cell cycle.

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Koji Yoshimoto, Rameen Beroukhim, Paul S Mischel, 2005, The New England journal of medicine.

Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas.

Motoo Nagane, Yoshitaka Narita, W. Cavenee, 2002, Cancer research.

Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.

Paul S Mischel, Timothy F Cloughesy, Joseph A Loo, 2009, Cancer research.

EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma.

Bruce Mickey, Kimmo J Hatanpaa, W. Cavenee, 2009, Cancer research.